卡尔加里的《普罗维登斯治疗法》将莉娅·古德曼加入到它的董事会上,以促进MRNA疗法的发展和患者获得治疗的机会。 Calgary’s Providence Therapeutics adds Leah Goodman to its board to boost mRNA therapy development and patient access.

普罗维登斯治疗公司是一家设在卡尔加里的MRNA公司,已任命Leah Goodman为其董事会成员。 Providence Therapeutics, a Calgary-based mRNA company, has appointed Leah Goodman to its Board of Directors. 古德曼是澳大利亚生命科学顾问生物精选公司的首席执行官,在商品化、监管事务和各种肿瘤学、免疫疗法和先进疗法的市场准入方面,带来了广泛的经验。 Goodman, CEO of Australian life science consultancy Biointelect, brings extensive experience in commercialization, regulatory affairs, and market access across oncology, immunotherapies, and advanced therapies. 她的职业生涯包括在亚太市场的Sanofi、Merck KGaA和Bristol Myers Squibb担任领导职务。 Her career includes leadership roles at Sanofi, Merck KGaA, and Bristol Myers Squibb in Asia-Pacific markets. 她拥有新南威尔士大学学位,并毕业于澳大利亚公司董事学院。 She holds degrees from the University of New South Wales and is a graduate of the Australian Institute of Company Directors. Goodman与普罗维登斯合作, 支持其通过INTENT脂肪纳米粒子平台加速患者获得创新的MRNA治疗的任务, Goodman joins Providence to support its mission of accelerating patient access to innovative mRNA therapies through its INTENT lipid nanoparticle platform, with ongoing programs in oncology, infectious diseases, and animal health.